Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs MGM Resorts International — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.64 (market cap $8.04B), while MGM Resorts International trades at $47.04 (market cap $11.94B). The key difference: MGM Resorts International is the larger of the two by market cap, and MGM Resorts International pays a 0.03% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | MGM | |
|---|---|---|
Market Cap | $8.04B | $11.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $50.69 |
52-Week Low | $241.71 | $30.72 |
Enterprise Value | $7.85B | $40.98B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
MGM Resorts International (MGM) trades at $47.24, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $48.93. Recent financials show revenue growth to $17.54B in 2025, though net income margin remains thin at 1.03%. The stock is buoyed by acquisition talks with Barry Diller's People Inc. at $48.30 per share, as reported by The Wall Street Journal on July 10, 2026, and positive cash flow projections for 2026.
Outlook: MGM offers moderate upside potential driven by acquisition interest and steady revenue, but risks include volatile earnings, high debt, and regulatory scrutiny. Investors should weigh the takeover premium against fundamental weakness in profitability and execution risks in the competitive casino sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
